All studies
Oncology · EHR and claims · US

Kong 2025

HR-positive HER2-negative advanced breast cancer

QBA performedITTSuperiorityAcademia, Industry2/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Overall survival
vs MONALEESA-2·HR·Efficacy
0.760.63–0.93
2.751.62–4.69
no overlapClose alignment4.45 SE apart

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
IPTW and propensity-score matching
Analysis method
Weighted Cox proportional hazards model
Missing data
Not reported
DAG
No
QBA
Yes

Data and sample

Data type
EHR and claims
Data sources
Linked EHR and claims
Geography
US
Eligible sample
3912
Treated
106
Control
3806
Emulations
1
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
COI institutions
Aetion
Funding
Declared: Private
Funders
Aetion

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2025_Kong_MONALEESA2
DOI
10.57264/cer-2025-0026
Affiliations
Aetion; University of Pennsylvania; Emory University
Sector
Academia, Industry
Target trials (study level)
MONALEESA-2
Registration
NCT01958021